Evidence map›Paper›PMID 28436465›Full record

ArticleScientific reports2017

The Clinical Efficacy of Fibrinogen Concentrate in Massive Obstetric Haemorrhage with Hypofibrinogenaemia.

Shigetaka Matsunaga, Yasushi Takai, Eishin Nakamura, Sumiko Era, Yoshihisa Ono, Koji Yamamoto, Hiroo Maeda, Hiroyuki Seki

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Review
  4. The Role of Systemic Inflammatory Indices in Predicting Composite Adverse Outcomes of Peripartum Hemorrhage Treated with Fibrinogen Concentrate.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Fibrinogen for the management of critical obstetric hemorrhage.The journal of obstetrics and gynaecology research · 2019
    Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shigetaka MatsunagaCenter for Maternal, Foetal and Neonatal Medicine, Saitama Medical Centre, Saitama Medical University, Kawagoe, Japan.
Yasushi TakaiCenter for Maternal, Foetal and Neonatal Medicine, Saitama Medical Centre, Saitama Medical University, Kawagoe, Japan.
Eishin NakamuraCenter for Maternal, Foetal and Neonatal Medicine, Saitama Medical Centre, Saitama Medical University, Kawagoe, Japan.
Sumiko EraCenter for Maternal, Foetal and Neonatal Medicine, Saitama Medical Centre, Saitama Medical University, Kawagoe, Japan.
Yoshihisa OnoCenter for Maternal, Foetal and Neonatal Medicine, Saitama Medical Centre, Saitama Medical University, Kawagoe, Japan.
Koji YamamotoDepartment of Transfusion Medicine and Cell Therapy, Saitama Medical Centre, Saitama Medical University, Kawagoe, Japan.
Hiroo MaedaDepartment of Transfusion Medicine and Cell Therapy, Saitama Medical Centre, Saitama Medical University, Kawagoe, Japan.
Hiroyuki SekiCenter for Maternal, Foetal and Neonatal Medicine, Saitama Medical Centre, Saitama Medical University, Kawagoe, Japan.
Saitama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Massive obstetric haemorrhage remains a major cause of maternal death attributable to hypofibrinogenaemia. Transfusion of large volumes of fresh frozen plasma (FFP) is required to normalise fibrinogen levels. We compared the efficacy of FFP (F group) with that of FFP plus fibrinogen concentrate (F + F group) in massive obstetric haemorrhage. In this retrospective study, we compared the medical charts (2004-2016) of 137 patients with <150 mg/dl fibrinogen treated with F + F (n = 47; after August 2009) or F (n = 56; before August 2009). Although fibrinogen concentrate was only administered in severe cases, the FFP/red blood cell concentrate (RCC) ratio was significantly lower in the F + F group than in the F group. A sub-group analysis of cases requiring ≥18 RCC units showed that the F + F group received significantly less FFP than the F group (40.2 ± 19.6 versus 53.4 ± 18.5 units; P = 0.047) and showed significantly less pulmonary oedema (24.0% vs 57.1%; P < 0.05) in the absence of any significant differences in pre-transfusion coagulation, estimated blood loss, or RCC transfusion volume. Administration of fibrinogen concentrate increased the rate of fibrinogen supplementation five-fold and reduced FFP dosage, the FFP/RCC ratio, and the incidence of pulmonary oedema.

Indexed as

Pregnancy ComplicationsAdultCoagulation Protein DisordersFemaleFibrinogenHemorrhageHumansPregnancyRetrospective StudiesTreatment OutcomeYoung AdultFibrinogen

Identifiers

PMID28436465
PMCPMC5402272
OpenAlexW2609151975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.